The global high mobility group protein B1 market is expected to grow at a significant CAGR during the forecast period (2022-2028). The rising prevalence of cancer such as leukemia and multiple myeloma, globally is a major factor driving market growth. As per the Leukemia & Lymphoma Society (LLS), total of 186,400 people in the US were diagnosed with leukemia, lymphoma or myeloma in 2021.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/high-mobility-group-protein-b1-market
Moreover, approximately every 3 minutes, one person in the US is diagnosed with leukemia, lymphoma or myeloma and every 9 minutes, someone in the US dies from a blood cancer. In 2021, Leukemia, lymphoma and myeloma caused the deaths of an estimated 57,750 people in the US. As a result, rising cancer rates are driving up demand for HMGB1. In cancer therapy, HMGB1 has been observed to regulate multiple signalling pathways, including proliferation, apoptosis, inflammation, immunity, autophagy, genome stability, metastasis, and metabolism, to promote both cell survival and death.
Market Coverage
- The market number available for – 2021-2028
- Base year- 2021
- Forecast period- 2022-2028
Segment Covered-
- By Type
- By Application
Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
Competitive Landscape– Affibody AB, Cantex pharmaceuticals, Dicerna pharmaceuticals, and others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Global High Mobility Group Protein B1 Market Report Segment
By Type
- Dociparstat Sodium
- RBM-005
- EV-007156
By Application
- Autoimmune Disorders
- Chemotherapy Effects
- Cancer Treatment
A full report of High Mobility Group Protein B1 Market is available at: https://www.omrglobal.com/industry-reports/high-mobility-group-protein-b1-market
High Mobility Group Protein B1 Market– Segment by Region
North America
- United States
- Canada
Europe
- Germany
- United Kingdom
- France
- Spain
- Italy
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Rest of Asia-Pacific
Rest of the World
- Middle East & Africa
- Latin America
Company Profiles
- Affibody AB
- Cantex Pharmaceuticals Inc.
- Dicerna Pharmaceuticals Inc.
- Evec Inc
- Ribomic Inc
Reasons to Buying From us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research
